Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.

PURPOSE Small intestinal bacterial overgrowth (SIBO) may coexist with irritable bowel syndrome (IBS) and eradication therapy has been reported as effective in reducing IBS symptoms. Aims of this study were to: (1) Assess the clinical profiles of IBS patients, who underwent breath testing with a glucose substrate--glucose breath test (GBT); (2) Evaluate hydrogen and methane parameters in various IBS groups; (3) Assess the role of inhibition of gastric acid in contributing to SIBO; (4) Investigate efficacy and safety of non-absorbable antibiotic rifamixin for eradication and symptom relief. METHODS 204 IBS patients met the ROME II criteria for IBS (170F & 34M; mean age 46.4; range 18-88) and underwent GBT. 8 of these patients with positive GBT were treated with rifaximin 200 mg, 4 times a day for 1 month and symptom assessments and GBT were repeated. RESULTS 93 (46%) had a positive GBT. 68 (73%) of these 93 IBS-diarrhea dominant (IBS-D), 12 (13%) were constipation dominant (IBS-C) and 13 (14%) IBS with alternating bowel pattern. 48% of SIBO positive patients were receiving PPI therapy compared to 40% of IBS patients with negative GBT. 61 (66%) produced only hydrogen, 27 (29%) methane only, and 5 (5%) both-hydrogen and methane. There were more methane producers in IBS-C then IBS-D group (58% vs 28%) while IBS-D had more hydrogen formers (71% vs 42%). 8 patients with SIBO (7F & IM; mean age 55, range 31-85) received rifamixin 800 mg/day. Repeat GBT was normal in 6 (75%), 1 patient (12.5%) normalized according to hydrogen criteria but methane remained positive. Symptoms score improved in 7 (87.5%) patients and no adverse events were noted. CONCLUSIONS (1) SIBO was present in nearly half of this large cohort of IBS patients based on the results of GBT; (2) Chronic PPI use was not associated with SIBO; (3) Methane formers on the GBT are more likely to be constipated; (4) Rifaximin is effective in treatment of SIBO in IBS and controlled trials are warranted.

[1]  B. Flourié,et al.  Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date , 2007, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[2]  E. Björnsson,et al.  Small intestinal bacterial overgrowth in patients with irritable bowel syndrome , 2006, Gut.

[3]  M. Pimentel,et al.  Neomycin Improves Constipation-Predominant Irritable Bowel Syndrome in a Fashion That Is Dependent on the Presence of Methane Gas: Subanalysis of a Double-Blind Randomized Controlled Study , 2006, Digestive Diseases and Sciences.

[4]  Henry C. Lin,et al.  Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[5]  K. McColl,et al.  Review article: proton pump inhibitors and bacterial overgrowth , 2006, Alimentary pharmacology & therapeutics.

[6]  Henry C. Lin,et al.  Management of small intestinal bacterial overgrowth , 2005, Current gastroenterology reports.

[7]  A. Gasbarrini,et al.  Rifaximin dose‐finding study for the treatment of small intestinal bacterial overgrowth , 2005, Alimentary pharmacology & therapeutics.

[8]  Henry C. Lin,et al.  Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. , 2004, JAMA.

[9]  Henry C. Lin,et al.  Normalization of Lactulose Breath Testing Correlates With Symptom Improvement in Irritable Bowel Syndrome: A Double-Blind, Randomized, Placebo-Controlled Study , 2003, American Journal of Gastroenterology.

[10]  Henry C. Lin,et al.  Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome , 2000, American Journal of Gastroenterology.

[11]  B. Flourié,et al.  Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome , 1999, American Journal of Gastroenterology.

[12]  S. Wexner,et al.  The lactulose hydrogen breath test as a measure of orocaecal transit time. , 1994, The European journal of surgery = Acta chirurgica.

[13]  G. Corazza,et al.  The diagnosis of small bowel bacterial overgrowth: Reliability of jejunal culture and inadequacy of breath hydrogen testing , 1990 .

[14]  G. Sturniolo,et al.  [Irritable bowel syndrome]. , 1988, Giornale di clinica medica.

[15]  D. Baker.  Rifaximin: a nonabsorbed oral antibiotic. , 2005, Reviews in gastroenterological disorders.